Dr. Farid Menaa, is a French citizen, proficient in various languages (fluency in French, English, Portuguese; acceptable knowledge in Spanish, German and Arabic) and has lived in four countries within two continents. Dr. Menaa is an experienced and skilled inter- and multi-disciplinary professional. Dr. Menaa earned his degrees mainly from France (Paris) with high distinctions from prestigious universities and institutions. He holds a Bsc. Eng. Bio, Bsc. Physiology and Cell Biology, Msc. Genetics/Molecular and Cell Biology, Msc Gerontology/Genetics, PhD Gerontology/Genetics/Radiation Oncology, EMBA Entrepreneurship, three international post-doctoral specialties (i.e. Oncology and drug discovery; Dermato-oncology and stem cells research; Hematology and genomics). Professor, Principal Investigator, Executive Director, Consultant, Advisor, Editor, Reviewer, Event Organizer and Entrepreneur, he was recently selected for “Who´s is Who in the World”. His mentors include world-renowned professionals such as Prof. Dr. Axel Kahn (MD, PhD – France), Prof. Dr. Juergen C. Becker (MD, PhD – Germany), and Prof. Dr. Fernando Ferreira Costa (MD, PhD – Brazil). Thereby, as a CFR and LNCC awarded investigator, he earned his doctorate of gerontology and oncology in 2003 with highest distinction from Sorbonne?university of Paris 7 & Nuclear Energy Authority/Ministry of Defence (Paris, France) after identifying new human genes involved in the radio-modulation of mammalian cancer cells while contributing with projects related to DNA repair systems. Then, as NIH fellow (2004-2007) in oncology and drug discovery, he pursued his career at Sidney Kimmel Cancer Center\Sanford-Burnham Medical Research Institute (San Diego, California, USA) where he pioneered a paradigmatic DNA-damage signaling pathway while contributing to other projects associated with cell cycle and proteolysis systems. Subsequently, as a DFG fellow (2007-2009) in dermatology, dermato-immunology and dermato-oncology at the University of Wuerzburg (Wuerzburg, Bavaria, Germany), he discovered a crucial association between skin cancer stem cells, diagnosis and prognosis. Recently, as a FAPESP fellow (2010-2012) in hematology and genomics at the State University of Campinas (UNICAMP) (Campinas, São Paulo, Brazil), he pioneered the identification of new genomic variants of stroke in adult patients with sickle cell anemia.

Nanomedicine, Nanotechnology, nanopharmacy